Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.66 USD | +1.05% | +3.67% | +3.67% |
May. 14 | Wedbush Adjusts Voyager Therapeutics' PT to $8 From $10, Keeps Neutral Rating | MT |
May. 13 | Transcript : Voyager Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.67% | 466M | |
+32.95% | 49.46B | |
+1.94% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+12.22% | 26.61B | |
-23.46% | 18.64B | |
+8.26% | 13.16B | |
+30.32% | 12.55B | |
+24.23% | 12.1B |
- Stock Market
- Equities
- VYGR Stock
- News Voyager Therapeutics, Inc.
- Chardan Adjusts Price Target on Voyager Therapeutics to $4 From $5.50 While Awaiting Info on New Pipeline, Maintains Neutral Rating